Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab for anti-NMDAR or anti-LGI1 autoimmune encephalitis
jRCT2011220016Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Autoimmune Encephalitis (AE), anti-NMDA receptor encephalitis and Anti-leucine-rich glioma inactivated 1 encephalitis comparing Satralizumab with Placebo (2 arms). Primary endpoints: Proportion of participants with mRS improvement at Week 24 without rescue therapy, Proportion of participants with mRS improvement at Week 52 without rescue therapy and 2 more. Started Sep 2022; status: recruiting.
02
Drugs
satralizumab
03
Conditions
Autoimmune Encephalitis (AE)anti-NMDA receptor encephalitisAnti-leucine-rich glioma inactivated 1 encephalitis
Beyond the preview
Go deeper on jRCT2011220016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220016.